Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial.
Bern-Thomas Nyang'wa, Frank Kloprogge, David A J Moore, Amaya Bustinduy, Ilaria Motta, Catherine Berry, Geraint R Davies
Author Information
Bern-Thomas Nyang'wa: Manson Unit, Médecins Sans Frontières, London, UK bern-thomas.nyangwa@lshtm.ac.uk. ORCID
Frank Kloprogge: Institute for Global Health, University College London, London, UK. ORCID
David A J Moore: Clinical research Department, London School of Hygiene & Tropical Medicine, London, UK.
Amaya Bustinduy: Clinical research Department, London School of Hygiene & Tropical Medicine, London, UK.
Ilaria Motta: Manson Unit, Médecins Sans Frontières, London, UK.
Catherine Berry: Manson Unit, Médecins Sans Frontières, London, UK.
Geraint R Davies: Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.
INTRODUCTION: Drug-resistant tuberculosis (TB) remains a global health threat, with little over 50% of patients successfully treated. Novel regimens like the ones being studied in the TB-PRACTECAL trial are urgently needed. Understanding anti-TB drug exposures could explain the success or failure of these trial regimens. We aim to study the relationship between the patients' exposure to anti-TB drugs in TB-PRACTECAL investigational regimens and their treatment outcomes. METHODS AND ANALYSIS: Adults with multidrug-resistant TB randomised to investigational regimens in TB-PRACTECAL will be recruited to a nested pharmacokinetic-pharmacodynamic (PKPD) study. Venous blood samples will be collected at 0, 2 and 23 hours postdose on day 1 and 0, 6.5 and 23 hours postdose during week 8 to quantify drug concentrations in plasma. Trough samples will be collected during week 12, 16, 20 and 24 visits. Opportunistic samples will be collected during weeks 32 and 72. Drug concentrations will be quantified using liquid chromatography-tandem mass spectrometry. Sputum samples will be collected at baseline, monthly to week 24 and then every 2 months to week 108 for MICs and bacillary load quantification. Full blood count, urea and electrolytes, liver function tests, lipase, ECGs and ophthalmology examinations will be conducted at least monthly during treatment.PK and PKPD models will be developed for each drug with nonlinear mixed effects methods. Optimal dosing will be investigated using Monte-Carlo simulations. ETHICS AND DISSEMINATION: The study has been approved by the Médecins sans Frontières (MSF) ETHICS Review Board, the LSHTM ETHICS Committee, the Belarus RSPCPT ETHICS committee and PharmaEthics and the University of Witwatersrand Human Research ETHICS committee in South Africa. Written informed consent will be obtained from all participants. The study results will be shared with public health authorities, presented at scientific conferences and published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: NCT04081077; Pre-results.
